/PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs

Capricor se acerca al cronograma de presentación de informes regulatorios y a las ganancias, mientras que Sarepta se dirige a los resultados bajo presión legal y de seguridad.

Price-action only: Capricor Therapeutics Inc. (CAPR) movements set the tone for institutional models. Behavioral Patterns of CAPR and Institutional Flows

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 28, 2026 to file lead plaintiff...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit...

BENSALEM, Pa., Sept. 3, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit

San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with...

San Francisco, California--(Newsfile Corp. - September 4, 2026) - Hagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with...

Capricor busca la aprobación judicial para seguir una vía de comercialización alternativa para Deramiocel y quiere que se rescindan partes del acuerdo.

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc....